The opioid epidemic is a public health emergency that claims the lives of more than 100 people in the United States every day—that's nearly 50,000 people each year—according to data from the National Center for Drug Abuse Statistics.
Since 1999, deaths from opioid-related drug overdoses involving prescription opioids such as pain relievers, synthetic opioids like fentanyl, and heroin have risen more than eightfold, according to the CDC. Ophelia conducted research based on government and scientific sources to help you understand how buprenorphine helps the body overcome opioid addiction.
Opioids are highly addictive because they trigger endorphins, hormones that suppress pain and induce feelings of pleasure, causing misusers to seek out the experience repeatedly. While opioids in the bloodstream can stimulate feelings of euphoria, they also induce respiratory depression, which affects the body's drive to breathe and can result in death; during an overdose, the body struggles to get the oxygen necessary to sustain the needs of the brain and other organs.
Treating opioid use disorder requires a combination of medication and supports, such as counseling, care coordination, and therapy. Drugs used to treat opioid use disorder include opioid agonists and partial agonists (which only have partial activation at opioid receptors), which help users by minimizing withdrawal and cravings. Buprenorphine is one notable partial agonist used in opioid addiction interventions.
Agonist substitution treatment for opioid use disorder uses buprenorphine
Agonist substitution treatment is an approach that replaces the misused drugs with ones sharing similar properties but much safer risk profiles and longer durations of action which help extinguish drug seeking behaviors. Buprenorphine—a synthetic opioid—is a partial agonist, according to the National Institutes of Health's National Library of Medicine.
The drug works by binding to the same opioid receptors in the brain, activating them less intensely than opioids. Thus buprenorphine decreases the craving for opioid stimulation and symptoms of withdrawal in the patient but does not trigger intense feelings of pleasure and euphoria like street drugs.
Buprenorphine is not swallowed as a pill, but rather taken sublingually, or under the tongue– it is directly absorbed into the bloodstream through soft tissues in the mouth.
Buprenorphine displaces the opioid molecules connected to receptors in the brain
Opioid receptors, found in the spinal cord, brain, and other organs, are a group of receptors that help with pain-blocking once opioids bind to and activate them, triggering a dopamine release and decreasing pain signaling.
When discussing opioids, it is essential to differentiate between exogenous opioids—those in drugs—and endogenous opioids, which are produced naturally by the body, notably beta-endorphin, met- and leu-enkephalins, and dynorphins.
People with opioid use disorder attempt to excessively replicate what is a natural process in the human body to suppress pain, allowing synthetic substances to bind to the receptors and trigger dopamine release. However, once they stop doing so, intense urges and withdrawal begin because the body is accustomed to artificially induced feelings of euphoria and pleasure.
Buprenorphine is a partial agonist with high receptor affinity—meaning it has a greater probability of binding to a receptor. But it also has low intrinsic activity, so it can displace morphine, methadone, and other full opioid agonists from the receptors, reigning in the effects of full-agonist opioids such as heroin.
In displacing opioids, buprenorphine reduces cravings
Buprenorphine, having a high affinity, intensely attaches to mu-opioid receptors, which regulate moods and feelings such as pain, motivation, and stress. These receptors also receive molecules from drugs like morphine and other opioids, which bind to them and trigger dopamine release.
After being absorbed sublingually, buprenorphine travels to the brain's mu-opioid receptors. Due to the high affinity of buprenorphine, the drug's molecules can displace those of other opioids attached to the receptors and only partially activate them, thereby reducing cravings.
Buprenorphine reduces or eliminates withdrawal symptoms in opioid users trying to quit
When buprenorphine molecules bind with mu-opioid receptors in the brain, they activate the receptors partially. If buprenorphine were a full agonist, it would produce a maximal response in a patient.
In other words, buprenorphine can give patients pain relief and craving reduction without stimulating feelings of euphoria or causing respiratory depression to the extent abused exogenous opioids do.
Additional research by Emilia Ruzicka. Story editing by Brian Budzynski. Copy editing by Kristen Wegrzyn. Cover image by Craig F. Walker // The Boston Globe via Getty Images.
Sources
